https://www.clinicaltrialsarena.com/news/bellerophon-therapeutics-fild-trial/ Another company fails to make a difference to Pulmonay Fibrosis management. Using ambulatory inhaled Nirtic Oxide (currently NOxide used successfully in ICU for temporary severe Pulmonary Hypertension management). Logically this would only address symptoms and possibly slow secondary right heart failure rather than address the causative fibrosis. ATX has a massive potential here.
Industry related information
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.02M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 294752 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.2¢ | 216959 | 2 |
View Market Depth
| Last trade - 10.09am 02/05/2024 (20 minute delay) ? |
| ATX (ASX) Chart |
Day chart unavailable